RxDoctor Payments Data

Kem Hor, MD

Gastroenterology · Colorado Springs, CONPI 1629155205

Payments from drug & device makers

$5,102in general payments, 2019–2025

Across 202 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$772
  • Gilead$455
  • Johnson & Johnson$380
  • Sanofi-aventis U.S. LLC$239
  • Janssen Scientific Affairs, LLC$238
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,02298%
  • Education$792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,102 in reported general payments places this provider in the 65th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$92,091
Medicare patients
208
Services billed
647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$353,226
SimponiGolimumab12$82,594
Humira(Cf) PenAdalimumab11$74,626
CreonLipase/Protease/Amylase14$35,003
LinzessLinaclotide16$12,739
Pantoprazole Sodium94$1,175
Balsalazide Disodium11$1,043
Sucralfate26$1,030
Omeprazole77$860
Famotidine37$648
Lactulose22$377
Ondansetron OdtOndansetron24$313
Colesevelam Hcl12$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$380$435,82125 claims
AbbVieCreon, Linzess$1,143$47,74230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →